Despite the clinical similarities and treatment differences between giant cell arteritis (GCA polymyalgia rheumatica (PMR), confusion exists regarding the impact of overlapping disorders. A large cohort study shows that GCA patients with PMR symptoms are more apt to have recalcitrant disease, more relapses and longer duration of glucocorticoid (GC), along with higher GC doses.
An economic evaluation of 25 099 rheumatoid arthritis patients found that treatment with biosimilar disease-modifying antirheumatic drugs (DMARDs) were cost-effective compared with the conventional DMARD, leflunomide. Does this suggest RA treatment guidelines need to be amended to allow biosimilars use immediately after the failure of methotrexate?
Dr. John Cush RheumNow
2 years 3 months ago
ICYMI: 2023 EULAR Psoriatic Arthritis Recommendations
https://t.co/abcs8RwJ5J https://t.co/wLOq4bK7qQ
Dr. John Cush RheumNow
2 years 3 months ago
ICYMI: Best Imaging in Giant Cell Arteritis - US, PET, MRI?
https://t.co/J4aE4jxNb0 https://t.co/b6axwp4Tuw
Dr. John Cush RheumNow
2 years 3 months ago
ICYMI: 2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update
https://t.co/iccSFuAogX https://t.co/ORzwvDKqVo
Dr. John Cush RheumNow
2 years 3 months ago
ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes
https://t.co/46g8ek286u https://t.co/FEFq4vkiPk
Dr. John Cush RheumNow
2 years 3 months ago
ICYMI: 9 Facts about Leflunomide
Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui.
https://t.co/WseVa589Fg. https://t.co/K4u00MbwEb
Dr. John Cush RheumNow
2 years 3 months ago
ICYMI: JAMA: SLE Review
https://t.co/GJJSOYZru2 https://t.co/mCgWy27yPr
Dr. John Cush RheumNow
2 years 3 months ago
ICYMI: BSR Guideline on Management of Sjogren’s Syndrome
https://t.co/MMG3NmCeDl https://t.co/zKlR8jOkLD
Dr. John Cush RheumNow
2 years 3 months ago
Review of Amyloidosis
The New England Journal of Medicine has published a review of systemic amyloidosis.
https://t.co/qtbdPrlKnj https://t.co/wcqvRAauWC
Dr. John Cush RheumNow
2 years 3 months ago
Predicting Palindromic Prognosis
Dr. David Liew discusses abstract OP0127, "PREDICTING PERSISTENT INFLAMMATORY ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM: DEVELOPMENT OF SCORES FOR RISK STRATIFICATION", at Eular 2024 in Vienna, Austria.
https://t.co/Yzr9feNjjF https://t.co/BKVbDv3e4E
Dr. John Cush RheumNow
2 years 3 months ago
ICYMI: Enthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis
An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA)
https://t.co/JjhkQM672t. https://t.co/dM25kIcC26
In patients with clinically stable systemic lupus erythematosus (SLE) and lupus nephritis, the withdrawal of mycophenolate mofetil was not significantly inferior to mycophenolate maintenance, but MMF withdrawal had numerically more reactivations, while MMF maintenance had more infections.
The trouble with rheumatology may be the words we live by. Welcome to the eulogy for rheumatology 'dead words'. We're here today to celebrate the loss of rheumatology past. These are dead words in rheumatology, words fortified unfortunately by history and habit. The lexicon of rheumatology is unique, it's challenging and it's mostly incomprehensible to those who don't know...but those are the cornerstones of the greatest of medical

